Intratumoral or intravenous administration of exoASO-STAT6 in syngeneic tumor models of colorectal cancer and hepatocellular carcinoma (HCC), respectively, resulted in substantial tumor growth inhibition and complete tumor remission (CR) in most of the treated animals. This evidence concerns the gene STAT6 and hepatocellular carcinoma.